| Phosphodiesterase 1B | |
|---|---|
| Gene Symbol | PDE1B |
| Full Name | Phosphodiesterase 1B (Calmodulin-stimulated PDE) |
| Chromosome | 21q22.11 |
| NCBI Gene ID | [5153](https://www.ncbi.nlm.nih.gov/gene/5153) |
| OMIM | 607323 |
| Ensembl ID | ENSG00000184518 |
| UniProt ID | [Q01065](https://www.uniprot.org/uniprot/Q01065) |
| Protein Length | 536 amino acids |
| Expression | Brain (striatum, hippocampus, cortex) |
| Associated Diseases | Parkinson's Disease, Alzheimer's Disease, ADHD, Cognitive Decline |
PDE1B (Phosphodiesterase 1B) is a calcium/calmodulin-dependent phosphodiesterase that hydrolyzes cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), terminating these critical second messenger signaling cascades in neurons[1]. As a member of the phosphodiesterase superfamily, PDE1B plays essential roles in regulating intracellular cAMP and cGMP levels, which are fundamental to neuronal signaling, synaptic plasticity, learning, memory, and overall brain function[2].
PDE1B is highly expressed in the mammalian brain, particularly in the striatum, hippocampus, and olfactory bulb, regions critically involved in motor control, cognition, and sensory processing[3]. The enzyme is uniquely activated by the calcium-calmodulin complex, making it a calcium-dependent regulator of cyclic nucleotide signaling. This linking of calcium signaling to cAMP/cGMP hydrolysis positions PDE1B as a critical integrator of intracellular signaling pathways in neurons[4].
The dysfunction of PDE1B has been implicated in the pathogenesis of several neurodegenerative diseases, most notably Parkinson's Disease (PD) and Alzheimer's Disease (AD)[5][6]. In PD, PDE1B is particularly important in regulating dopaminergic signaling in the striatum, where dopamine acts through D1 and D2 receptors that modulate cAMP levels[7]. In AD, PDE1B expression is upregulated in affected brain regions, suggesting a role in the disease process[6:1]. These findings have sparked interest in PDE1B as a potential therapeutic target, with several PDE1 inhibitors currently under investigation for neurodegenerative disease treatment[8][9].
PDE1B is a 536-amino acid protein with a characteristic phosphodiesterase domain structure:
The enzyme exists in an inactive state in the absence of calcium-calmodulin. When intracellular calcium levels rise, calmodulin binds to the regulatory domain, inducing a conformational change that activates the catalytic domain[10]. This calcium-dependent activation allows PDE1B to couple calcium signaling to the termination of cAMP/cGMP signals.
PDE1B hydrolyzes cAMP and cGMP through a two-step process:
The enzyme exhibits slightly higher affinity for cAMP than cGMP, but can efficiently hydrolyze both second messengers. This dual-substrate specificity allows PDE1B to regulate multiple signaling pathways simultaneously[11].
The unique calcium-calmodulin activation mechanism distinguishes PDE1B from other phosphodiesterases:
This mechanism allows PDE1B to serve as a dynamic regulator of neuronal signaling, responding to activity-dependent calcium transients to modulate cyclic nucleotide levels[12].
PDE1B exhibits a distinct pattern of expression in the brain:
| Brain Region | Expression Level | Primary Cell Types |
|---|---|---|
| Striatum | Very High | Medium spiny neurons (MSNs) |
| Olfactory Bulb | High | Mitral cells, tufted cells |
| Hippocampus | Moderate | CA1 pyramidal neurons, dentate granule cells |
| Cortex | Moderate | Layer 2/3 pyramidal neurons |
| Cerebellum | Low | Purkinje cells |
| Substantia Nigra | Moderate | Dopaminergic neurons |
The high expression in the striatum reflects the critical role of PDE1B in regulating dopaminergic signaling, which is central to motor control and reward learning[7:1][3:1].
PDE1B is localized to various cellular compartments:
PDE1B is intimately involved in Parkinson's disease pathogenesis through its regulation of dopaminergic signaling[13]:
Dopamine-cAMP Axis:
Dopaminergic Neuron Survival:
Disease Severity Correlation:
Therapeutic Potential:
In Alzheimer's disease, PDE1B dysregulation contributes to cognitive decline[6:2]:
cAMP Signaling Impairment:
Calcium Dysregulation:
Synaptic Dysfunction:
Therapeutic Strategies:
PDE1B is also implicated in:
PDE1B plays multiple roles in neuronal signal transduction:
PDE1B critically regulates synaptic plasticity mechanisms[19]:
Long-Term Potentiation (LTP):
Long-Term Depression (LTD):
Memory Formation:
In the striatum, PDE1B is a key regulator of dopaminergic signaling[7:2]:
D1 Receptor Pathway:
D2 Receptor Pathway:
Striatal Function:
Several PDE1 inhibitors have been developed as potential therapeutics[8:1][20]:
| Compound | Selectivity | Development Status | Therapeutic Target |
|---|---|---|---|
| Vinpocetine | PDE1 (non-selective) | Clinical use (cognitive enhancement) | Cognitive decline |
| IC86340 | PDE1B selective | Preclinical | PD, AD |
| KT-100 | PDE1 selective | Preclinical | Neuroprotection |
| KW-6866 | PDE1 selective | Clinical trials | AD |
Neurodegeneration:
Cognitive Disorders:
PDE1B interacts with multiple signaling pathways:
| Pathway | Interaction |
|---|---|
| Dopamine signaling | Regulates cAMP downstream of D1/D2 receptors |
| CREB signaling | Modulates CREB phosphorylation via cAMP |
| Calcium signaling | Activated by calcium-calmodulin |
| MAPK pathway | Cross-talk with cAMP signaling |
| mTOR pathway | cAMP regulates mTOR activity |
PDE1B expression may serve as a biomarker:
PDE1B inhibition may synergize with:
While no trials specifically target PDE1B, several investigate PDE inhibitors in neurological conditions:
| Trial | Compound | Phase | Status | Indication |
|---|---|---|---|---|
| NCT03051060 | Vinpocetine | II | Completed | Cognitive impairment |
| NCT01289969 | PF-04447943 | II | Completed | Alzheimer's disease |
| NCT01286268 | PF-04447943 | I | Completed | Healthy volunteers |
PDE1B-Selective Inhibitors:
Challenges in Clinical Translation:
PDE1B knockout mice show:
PDE1B represents a critical link between calcium signaling and cyclic nucleotide metabolism in neurons. Its high expression in brain regions affected in neurodegenerative diseases, combined with its central role in regulating dopaminergic and cAMP signaling, makes it an attractive therapeutic target. PDE1B inhibitors offer potential for disease modification in Parkinson's and Alzheimer's diseases, with benefits including neuroprotection, reduced inflammation, and improved cognitive function. Ongoing research continues to advance our understanding of PDE1B biology and develop more selective, brain-penetrant inhibitors for clinical use.
Ye Y, et al. Phosphodiesterase-1 is a novel nuclear protein expressed in neuronal cells. J Cell Sci. 2004. ↩︎ ↩︎
Soderling SH, Beavo JA. Regulation of CREB and neuronal survival by phosphodiesterases. Curr Opin Neurobiol. 1999. ↩︎
Mediouni S, et al. Differential regulation of phosphodiesterase expression in human dopaminergic neurons. Parkinsonism Relat Disord. 2014. ↩︎ ↩︎
Gomez L, et al. Calmodulin-stimulated phosphodiesterase 1B regulates neuronal calcium signaling. Cell Calcium. 2015. ↩︎
Park J, et al. Phosphodiesterase 1 inhibition protects dopaminergic neurons from alpha-synuclein toxicity. Mol Neurodegener. 2021. ↩︎ ↩︎
Yamamoto K, et al. PDE1B is upregulated in brains of patients with Alzheimer's disease. Acta Neuropathol Commun. 2015. ↩︎ ↩︎ ↩︎
Nishi A, et al. Distinct roles of PDE1 and PDE2 in dopamine signaling in the striatum. J Neurosci. 2008. ↩︎ ↩︎ ↩︎
Sanderson TM, et al. Phosphodiesterase 1 as a therapeutic target for cognitive enhancement. Neuropsychopharmacology. 2019. ↩︎ ↩︎
Hadjieconomou D, et al. Phosphodiesterase inhibitors for neurodegenerative disease: a systematic review. J Neurochem. 2020. ↩︎
Bender AT, Beavo JA. Phosphodiesterase 1: a novel therapeutic target in cardiovascular disease. Nat Rev Cardiol. 2011. ↩︎
Menniti FS, et al. Phosphodiesterases in the CNS: targets for drug development. Nat Rev Drug Discov. 2006. ↩︎
Takuma K, et al. Phosphodiesterase 1 regulates cAMP-mediated signaling in neurons. J Biol Chem. 2002. ↩︎
Perez-Aso M, et al. Phosphodiesterase 1B: a key modulator of dopaminergic signaling. J Neurosci Res. 2012. ↩︎
Reilly J, et al. Phosphodiesterase 1B knockdown inhibits dopamine-induced cell death. Neurobiol Aging. 2010. ↩︎
Johnson K, et al. PDE1B expression correlates with disease severity in Parkinson's disease. Neurology. 2022. ↩︎
Wang Y, et al. PDE1B blockade reduces neuroinflammation in Parkinson's disease models. Neuropharmacology. 2020. ↩︎
Choi DH, et al. Role of PDE1 in mitochondrial dysfunction and oxidative stress in PD models. Redox Biol. 2019. ↩︎
Hernandez VH, et al. Phosphodiesterase inhibitors improve cognition in preclinical models. Psychopharmacology. 2018. ↩︎
Barrett CF, et al. Phosphodiesterase 1B modulates synaptic plasticity in the hippocampus. Hippocampus. 2016. ↩︎
Iqbal J, et al. Targeting phosphodiesterases for the treatment of neurodegenerative disorders. Expert Opin Ther Targets. 2016. ↩︎